It was furthermore shown that the exon 5 inclusion variant of ECT2 increased tumor growth of doxorubicin-resistant breast cancer cells and resistance to chemotherapy in vivo, suggesting that this AS event contributed to the resistance induced by SYF2 or ZRANB2 overexpression [279]. Here, ZRANB2 is linked to breast cancer.